1.
Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, Kooy M van M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica [Internet]. 2019Oct.30 [cited 2026Nov.16];104(11):2265-73. Available from: https://haematologica.org/article/view/9129